<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05048082</url>
  </required_header>
  <id_info>
    <org_study_id>ON-1005</org_study_id>
    <nct_id>NCT05048082</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate Diagnostic Performance and Safety of Pegsitacianine, an Intraoperative Fluorescence Imaging Agent for the Detection of Lung Malignancies in Patients Undergoing Routine Surgery</brief_title>
  <official_title>A Phase 2, Single-Dose, Open-Label Study to Evaluate Diagnostic Performance and Safety of Pegsitacianine, an Intraoperative Fluorescence Imaging Agent for the Detection of Lung Malignancies, in Patients Undergoing Routine Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>OncoNano Medicine, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>OncoNano Medicine, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This Phase 2 study is an open-label, single-arm trial where each patient is his/her own&#xD;
      &quot;intrapatient&quot; control. All patients will receive a single dose of pegsitacianine prior to&#xD;
      standard of care surgery.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 2021</start_date>
  <completion_date type="Anticipated">July 2022</completion_date>
  <primary_completion_date type="Anticipated">April 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>An interventional, open-label, single arm trial where each patient is his/her own intrapatient control. All patients will receive a single dose of pegsitacianine administered intravenously prior to standard of care (SOC) surgery.</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of Patients experiencing at least one Clinically Significant Event (CSE)</measure>
    <time_frame>1 day</time_frame>
    <description>Discovery of a clinically significant event at the level of the patient. May include detection of primary tumors, discovery of occult disease, or tumor negative SOC biopsies.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frequency and Severity of adverse events related to Pegsitacianine</measure>
    <time_frame>30 days</time_frame>
    <description>Treatment emergent adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pegsitacianine fluorescence and imaging performance</measure>
    <time_frame>7 days</time_frame>
    <description>Sensitivity, specificity, negative and positive predictive values of the imaging agent at the level of the individual patient specimens will be calculated</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Fluorescence imaging with pegsitacianine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pegsitacianine 1 mg/ml infused 24-72 hours prior to surgery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pegsitacianine</intervention_name>
    <description>An intraoperative nanoparticle-based fluorescence imaging agent comprised of micelles covalently conjugated to indocyanine green (ICG).</description>
    <arm_group_label>Fluorescence imaging with pegsitacianine</arm_group_label>
    <other_name>ONM-100</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Biopsy confirmed diagnosis, or a high clinical suspicion of a lung malignancy based on&#xD;
             MRI, CT and/or PET imaging&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known hypersensitivity or allergy to indocyanine green (ICG), polymethylmethacrylate&#xD;
             (PMMA; found in dental and bone cements) or polyethylene glycol (PEG)&#xD;
&#xD;
          -  Tumor locations the surgeon deems unfeasible to image intraoperatively&#xD;
&#xD;
          -  Excessive and/or generalized disease deemed inoperable by the surgeon&#xD;
&#xD;
          -  Life expectancy less than 12 weeks&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>OncoNano Medicine, Inc.</last_name>
    <phone>6822851411</phone>
    <email>trials@OncoNanomed.com</email>
  </overall_contact>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 7, 2021</study_first_submitted>
  <study_first_submitted_qc>September 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 17, 2021</study_first_posted>
  <last_update_submitted>September 16, 2021</last_update_submitted>
  <last_update_submitted_qc>September 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

